Press Release: Microbiome Insights publishes a comprehensive microbiome study guide to help researchers plan and conduct studies

Vancouver, BC -- Microbiome Insights Inc., a leading global provider of end-to-end services for microbiome DNA sequencing, including state-of-the-art bioinformatic analysis, has recently published the "How to Plan and Conduct a Microbiome Study" guide. The publication's goal is to support scientists and companies in planning and conducting studies to advance their microbiome research and development.

 

In announcing this publication, Microbiome Insights CEO Malcolm Kendall said, "we hope our guide will help scientists across academia and industry to understand and appreciate some of the differences and complexities of conducting microbiome studies - every step can impact the quality of the data. Microbiome research  is a new, fast growing and important area of science that will have a significant impact on our health and our environment. We could not be more excited to help our clients move this area of science forward".

 

Microbiome Insights's team has worked on over 500 microbiome studies and leveraged this experience and accumulated expertise to develop this unique document. The company also relied on the expertise of its co-founder Dr. William (Bill) Mohn, a Professor in the Department of Microbiology & Immunology at the University of British Columbia, who has over 135 peer-reviewed publications and has led or co-led numerous interdisciplinary collaborative research projects.

 

About Microbiome Insights

Microbiome Insights, Inc. is a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatic analysis. The company is headquartered in Vancouver, Canada where samples from around the world are processed in its College of American Pathologist (CAP) accredited laboratory. Working with clients from pharma, biotech, nutrition, cosmetic and agriculture companies as well as with world leading academic and government research institutions, MBI has supported over 670 microbiome studies from basic research to commercial R&D and clinical trials. The company's team of expert bioinformaticians and data scientists deliver industry leading insights including biomarker discovery, machine-learning based modelling and customized bioinformatics analysis.